Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin for Diabetes After Liver Transplantation
ChiCTR-IPR-17010537Phase 4Not yet recruiting
- Sponsor
- The Third Medical Center of the Chinese People's Liberation Army General Hospital
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of linagliptin in type 2 diabetes mellitus (T2DM) and post-transplantation diabetes mellitus (PTDM) (2 arms), sponsored by The Third Medical Center of the Chinese People's Liberation Army General Hospital. Primary endpoint: HbA1c. Planned start Mar 2017; status: not yet recruiting.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)post-transplantation diabetes mellitus (PTDM)
Beyond the preview
Go deeper on ChiCTR-IPR-17010537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010537.